Lucemyra Tablet, Film Coated
Product Images NDC 78670-050

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lucemyra (NDC 78670-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Uswm, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lucemyra 01)

Chemical structure of lofexidine hydrochloride, the active ingredient in Lucemyra, showing the molecular arrangement including a chlorine-substituted aromatic ring and an imidazoline ring.*

FDA Label Image

Figure 1 (Lucemyra 02)

A Kaplan-Meier curve illustrating the proportion of subjects completing the treatment period over study days 1 through 7. It compares three groups: Lofexidine 2.16 mg, Lofexidine 2.88 mg, and placebo, showing greater completion rates for both Lofexidine dosages relative to placebo throughout the study period.*

FDA Label Image

Figure 2 (Lucemyra 03)

A line chart depicting the mean SOWS-Gossop scores over a seven-day study period. The chart compares two doses of lofexidine hydrochloride (2.16 mg and 2.88 mg) with placebo, showing score trends and 95% confidence intervals for each group across study days.*

FDA Label Image

Figure 3 (Lucemyra 04)

A line graph comparing the proportion of subjects completing a treatment period over eight study days. The graph has two lines: a solid line for Lofexidine 2.88 mg and a dashed line for placebo, showing higher completion rates for Lofexidine throughout the study.*

FDA Label Image

Figure 4 (Lucemyra 05)

A line graph comparing the mean SOWS-Gossop scores over study days between lofexidine 2.88 mg and placebo groups. The x-axis shows study days 1 through 5, and the y-axis shows the mean scores with 95% confidence intervals, illustrating changes in scores for both treatment and placebo over time.*

FDA Label Image

Principal Display Panel (0.18 mg Tablet Bottle Carton)

Lucemyra (lofexidine) tablets 0.18 mg film-coated oral tablets packaging label. The label shows the brand and generic names, strength, NDC 78670-050, and the labeler USWM, LLC. The carton states prescription-only status, directions to store in the original container, protect from heat and moisture, and contains 96 tablets. It includes storage conditions and a barcode. Additional lot, serial, and expiration information areas are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.